Opendata, web and dolomites

NATURE-ETN SIGNED

Nucleic Acids for Future Gene Editing, Immunotherapy and Epigenetic Sequence Modification

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 NATURE-ETN project word cloud

Explore the words cloud of the NATURE-ETN project. It provides you a very rough idea of what is the project "NATURE-ETN" about.

fellows    boundaries    cell    despite    leaders    nature    business    acid    applicability    cells    deletions    immunotherapy    genomics    disruptive    planning    therapeutic    training    outstanding    serious    tools    originating    nucleic    breakthrough    materials    dna    therapies    today    outcomes    career    unrivalled    give    gene    pioneering    commercial    combination    insertions    15    questions    world    quality    editing    chemists    biomaterials    intersectoral    engineering    crystallography    epigenetic    scientific    nas    basic    stage    regarding    manipulation    chemistry    smes    grow    tech    extend    medicine    receive    undesired    crispr    skills    expertise    off    environment    meet    predicted    cas9    etn    laboratories    biologists    cancer    disciplinary    treatment    disease    na    deep    21st    base    discoveries    therapy    century    yield    biotech    combined    generation    excellence    industry    technologies    paradigm    skillset    transferable    culture    leverage    workshops    immunotherapies    prolonged    mutations    sequencing    translation    human    limitations    functioning   

Project "NATURE-ETN" data sheet

The following table provides information about the project.

Coordinator
DUBLIN CITY UNIVERSITY 

Organization address
address: Glasnevin
city: DUBLIN
postcode: 9
website: www.dcu.ie

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Ireland [IE]
 Total cost 4˙041˙816 €
 EC max contribution 4˙041˙816 € (100%)
 Programme 1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
 Code Call H2020-MSCA-ITN-2019
 Funding Scheme MSCA-ITN-ETN
 Starting year 2020
 Duration (year-month-day) from 2020-04-01   to  2024-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    DUBLIN CITY UNIVERSITY IE (DUBLIN) coordinator 824˙052.00
2    THE UNIVERSITY OF READING UK (READING) participant 606˙345.00
3    LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN DE (MUENCHEN) participant 505˙576.00
4    USTAV ORGANICKE CHEMIE A BIOCHEMIE, AV CR, V.V.I. CZ (PRAHA 6) participant 469˙743.00
5    ATDBIO LIMITED UK (SOUTHAMPTON HAMPSHIRE) participant 303˙172.00
6    THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD UK (OXFORD) participant 303˙172.00
7    ECOLE NATIONALE SUPERIEURE DE CHIMIE DE PARIS FR (PARIS CEDEX 05) participant 274˙802.00
8    NATIONAL INSTITUTE FOR BIOPROCESSING RESEARCH AND TRAINING LIMITED IE (BLACKROCK DUBLIN) participant 274˙684.00
9    BASECLICK GMBH DE (NEURIED) participant 252˙788.00
10    UNIWERSYTET WARSZAWSKI PL (WARSZAWA) participant 227˙478.00

Map

 Project objective

Nucleic acid (NAs) therapies are predicted to yield major advances in the treatment of human disease and new approaches in NA design are required to extend the boundaries of today`s gene editing technologies, cancer immunotherapies, and epigenetic base manipulation tools. Current gene editing technologies involving CRISPR-Cas9, despite their wide applicability, have serious limitations involving off-target or prolonged effects that produce mutations, insertions, and deletions leading to undesired therapeutic outcomes. Questions also remain regarding the development and delivery of NAs for manipulation of T-cells, now seen as the new paradigm in cancer research. NATURE-ETN will meet this challenge by engineering new biomaterials and therapies to extend the boundaries of i.) gene editing technology, ii.) cancer immunotherapy, and iii.) epigenetic base manipulation. Our research programme involves world-leading chemists and biologists in combination with high-tech/biotech SMEs and industry partners. We will use our combined expertise in NA chemistry, DNA crystallography, materials chemistry, cell culture, and epigenetic sequencing to develop an outstanding multi-disciplinary environment were 15 Early Stage Researchers will receive unrivalled research training in the most exciting gene therapy research today. The intersectoral training provided will encompass scientific and transferable skills, an understanding of industry, and features targeted workshops in sequencing and genomics along with quality/business management and future career planning. NATURE-ETN will leverage breakthrough discoveries—some originating from our own laboratories—to provide training excellence to give our fellows a deep skillset in the translation of basic research into high functioning commercial NA biomaterials. NATURE-ETN will develop the next generation of pioneering scientific leaders in Europe where they will grow our commercial need for disruptive technologies in 21st century medicine.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NATURE-ETN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NATURE-ETN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.1.)

ORBITAL (2019)

Ocular Research By Integrated Training And Learning

Read More  

INSPIRE (2020)

INnovation in Safety Pharmacology for Integrated cardiovascular safety assessment to REduce adverse events and late stage drug attrition.

Read More  

ENTWINE (2018)

The European Training Network on Informal Care

Read More